MannKind Corp. (NASDAQ:MNKD) weathered multiple setbacks to finally gain FDA approval for its inhaled insulin product, Afrezza. MannKind shares mostly hovered above $10 per share in 2004-06, buoyed in part by expectations for another inhaled insulin product, Exubera. But in October 2007, Pfizer Inc. (NYSE:PFE) ended further investment in Exubera, saying the diabetes drug had "failed to gain the acceptance of patients and physicians." MannKind shares declined to an all-time low of $1.57 in May 2012, with the stock mostly trading below $10 during 2007-13, when the company received two complete response letters. With FDA approval of the product last month, the stock is again